- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06281665
Traitement à l'aspirine après la prééclampsie : essai TAP (TAP)
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a pilot randomized, single-center, double-blind placebo-control study of low dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or identical appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Alisse K Hauspurg, MD
- Numéro de téléphone: 412-641-1381
- E-mail: janickia@upmc.edu
Sauvegarde des contacts de l'étude
- Nom: Sila Yavan, MS
- Numéro de téléphone: 4124174981
- E-mail: yavans@upmc.edu
Lieux d'étude
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- Recrutement
- University of Pittsburgh Magee-Womens Hospital
-
Contact:
- Sila Yavan, MS
- Numéro de téléphone: 4124174981
- E-mail: yavans@upmc.edu
-
Chercheur principal:
- Alisse K Hauspurg, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Postpartum individuals ≥18 years old
- Preeclampsia diagnosis
Exclusion Criteria:
- Fetal anomaly
- Multiple gestation
- Pre-pregnancy hypertension
- Allergy or contraindication to low-dose aspirin
- Pre-pregnancy diabetes
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo Group
Similar appearing placebo pill daily for 6 months will be given to subjects. |
The control group will receive similar appearing placebo daily for 6 months. |
|
Expérimental: Intervention Group
Low-dose [81 mg] aspirin pill daily for 6 months will be given to subjects |
The intervention group will receive low-dose [81 mg] aspirin pill daily for 6 months. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percent of participants eligible, enrolled and retained (feasibility)
Délai: Baseline to approximately 6 months postpartum
|
To determine the feasibility of conducting a single-site randomized controlled trial of 6 months of postpartum low-dose aspirin vs. placebo in women with preeclampsia. |
Baseline to approximately 6 months postpartum
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Study visit systolic BP
Délai: 2 months postpartum
|
Mean study visit systolic BP |
2 months postpartum
|
|
Study visit diastolic BP
Délai: 2 months postpartum
|
Mean study visit diastolic BP |
2 months postpartum
|
|
Study visit systolic BP
Délai: 6 months postpartum
|
Mean study visit systolic BP |
6 months postpartum
|
|
Study visit diastolic BP
Délai: 6 months postpartum
|
Mean study visit diastolic BP |
6 months postpartum
|
|
Study visit mean arterial pressure
Délai: 2 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
2 months postpartum
|
|
Study visit mean arterial pressure
Délai: 6 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
6 months postpartum
|
|
Anti-hypertensive medication use
Délai: 2 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
2 months postpartum
|
|
Anti-hypertensive medication use
Délai: 6 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
6 months postpartum
|
|
Therapeutic intensity score
Délai: 2 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
2 months postpartum
|
|
Therapeutic intensity score
Délai: 6 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
6 months postpartum
|
|
Mean home systolic blood pressure
Délai: delivery through 6 months postpartum
|
Mean home systolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home diastolic blood pressure
Délai: delivery through 6 months postpartum
|
Mean home diastolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home mean arterial pressure
Délai: delivery through 6 months postpartum
|
Mean home mean arterial pressure |
delivery through 6 months postpartum
|
|
Mean daytime systolic blood pressure
Délai: 6 months postpartum
|
Mean daytime systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal systolic blood pressure
Délai: 6 months postpartum
|
Mean nocturnal systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime diastolic blood pressure
Délai: 6 months postpartum
|
Mean daytime diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal diastolic blood pressure
Délai: 6 months postpartum
|
Mean nocturnal diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal mean arterial pressure
Délai: 6 months postpartum
|
Mean nocturnal mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime mean arterial pressure
Délai: 6 months postpartum
|
Mean daytime mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall mean arterial pressure
Délai: 6 months postpartum
|
Mean overall mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall systolic blood pressure
Délai: 6 months postpartum
|
Mean overall systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall diastolic blood pressure
Délai: 6 months postpartum
|
Mean overall diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Classification of hypertension
Délai: 2 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
2 months postpartum
|
|
Classification of hypertension
Délai: 6 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
6 months postpartum
|
|
Endothelial function EC50%
Délai: 2 months postpartum
|
EC50% from microiontophoresis |
2 months postpartum
|
|
Endothelial function EC50%
Délai: 6 months postpartum
|
EC50% from microiontophoresis |
6 months postpartum
|
|
Endothelial function Emax
Délai: 2 months postpartum
|
Emax from microiontophoresis |
2 months postpartum
|
|
Endothelial function Emax
Délai: 6 months postpartum
|
Emax from microiontophoresis |
6 months postpartum
|
|
Endothelial function change in Emax
Délai: 2 to 6 months postpartum
|
Change in Emax between visits |
2 to 6 months postpartum
|
|
Endothelial function change in EC50%
Délai: 2 to 6 months postpartum
|
Change in EC50% between visits |
2 to 6 months postpartum
|
|
Change in systolic blood pressure
Délai: 2 to 6 months postpartum
|
Change in study visit mean systolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in diastolic blood pressure
Délai: 2 to 6 months postpartum
|
Change in study visit mean diastolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in mean arterial pressure
Délai: 2 to 6 months postpartum
|
Change in study visit mean arterial pressure between visits |
2 to 6 months postpartum
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Alisse K Hauspurg, MD, UPMC Magee Women's Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales féminines et complications de la grossesse
- Infections
- Éclampsie
- Pré-éclampsie
- Hypertension induite par la grossesse
- Hypertension
- Maladies cardiovasculaires
- Maladies vasculaires
- Complications de grossesse
- Toxémie
- Produits chimiques organiques
- Hydrocarbures
- Hydrocarbures, cyclique
- Hydrocarbures, aromatique
- Phénols
- Dérivés de benzène
- Salicylates
- Hydroxybenzoates
- Aspirine
Autres numéros d'identification d'étude
- STUDY23080099
- K23HL168356 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Deidentified data (including data dictionaries) will be shared at the discretion of the primary investigator. Data will include blood pressure, weight, demographics, physical activity, and pregnancy related information. Additional documents (such as the study protocol) will be made available.
Délai de partage IPD
Within a year after outcomes are published and no later than 3 years after the end of clinical activities.
Critères d'accès au partage IPD
NHLBI data repository request process
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .